Description
While it’s increasingly clear that disruptive technologies from Silicon Valley will radically change the way that we make and test medicines, biopharma and healthcare need to level up in digital. Novartis made “Going Big on Data and Digital” one of the five top priorities of the company. But what does this mean in reality? The presenters will share with you some first insights into the Novartis digital strategy, including five disruptive scenarios that the company is exploring and look forward to a vivid discussion of what this could imply for the IP and Legal field. The idea is to learn from each other and to initiate fruitful discussions in an increasingly important area of research and innovation. Programme: 09:00 – 09:15 Welcome! – Legal dimensions of the Digital Leap in the Health & Life Sciences CeBIL Director, Professor Timo Minssen 09:15 – 09:45 “Novartis Digital” Novartis Head of Legal Digital, Matt Owens & Novartis Head of IP Strategy, Isabelle Schubert 09:45 – 10:15 Discussion 10:15 – 11:00 Mingle & Refreshments| Period | 31 Aug 2018 |
|---|---|
| Event type | Workshop |
| Location | Copenhagen, DenmarkShow on map |